Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yoonji Eum"'
Autor:
Chiara Ambrogio, Pasi A. Jänne, Mark M. Awad, Prafulla C. Gokhale, David Santamaria, Marie-Julie Nokin, Elodie Richard, Yunhan Chen, Kshiti H. Dholakia, Jens Köhler, Amanda J. Redig, Chhayheng Chhoeu, Joao Victor Alessi, Yue Xu, Jiaqi Li, Heidi M. Haikala, Mika Lin, Haiyun Wang, Raymond Paranal, Xinan Wang, Yoonji Eum, Enrico Patrucco, Alessia Mira, Jeffrey J. Okoro, Jieun Son, Biagio Ricciuti
Supplementary Data from Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e908ecdb4bf36d5ab7cc98336d10d7d
https://doi.org/10.1158/1078-0432.22484111.v1
https://doi.org/10.1158/1078-0432.22484111.v1
Autor:
Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son
Supplementary Data from A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non–Small Cell Lung Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fa51d44206e743a06a491f4c4226891
https://doi.org/10.1158/0008-5472.22431270
https://doi.org/10.1158/0008-5472.22431270
Autor:
Chiara Ambrogio, Pasi A. Jänne, Mark M. Awad, Prafulla C. Gokhale, David Santamaria, Marie-Julie Nokin, Elodie Richard, Yunhan Chen, Kshiti H. Dholakia, Jens Köhler, Amanda J. Redig, Chhayheng Chhoeu, Joao Victor Alessi, Yue Xu, Jiaqi Li, Heidi M. Haikala, Mika Lin, Haiyun Wang, Raymond Paranal, Xinan Wang, Yoonji Eum, Enrico Patrucco, Alessia Mira, Jeffrey J. Okoro, Jieun Son, Biagio Ricciuti
Purpose:Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly heterogeneous, and data on the potential isoform-dependent therapeutic vulnerabilities are st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a622d7dd524d9e4c7db5d7f6e4ccfdc
https://doi.org/10.1158/1078-0432.c.6531326
https://doi.org/10.1158/1078-0432.c.6531326
Autor:
Pasi A. Jänne, Nathanael S. Gray, Michael J. Eck, Michael D. Cameron, Prafulla C. Gokhale, Man Xu, Stephen Wang, Michael J. Poitras, Pinar Ö. Eser, Nicholas P. Kwiatkowski, John M. Hatcher, Mika Lin, Alyssa Verano, Heidi M. Haikala, Yoonji Eum, Tyler S. Beyett, Jaebong Jang, Jieun Son
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97a8ef884fce9cee6f7c5310978d793e
https://doi.org/10.1158/0008-5472.c.6513855.v1
https://doi.org/10.1158/0008-5472.c.6513855.v1
Autor:
Jieun Son, Jaebong Jang, Tyler S. Beyett, Yoonji Eum, Heidi M. Haikala, Alyssa Verano, Mika Lin, John M. Hatcher, Nicholas P. Kwiatkowski, Pinar Ö. Eser, Michael J. Poitras, Stephen Wang, Man Xu, Prafulla C. Gokhale, Michael D. Cameron, Michael J. Eck, Nathanael S. Gray, Pasi A. Jänne
Publikováno v:
Cancer Research. 82:1633-1645
In-frame insertions in exon 20 of HER2 are the most common HER2 mutations in patients with non–small cell lung cancer (NSCLC), a disease in which approved EGFR/HER2 tyrosine kinase inhibitors (TKI) display poor efficiency and undesirable side effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5dd25edc86a54a2b4204011c49a45ac0
https://doi.org/10.1158/0008-5472.can-21-2693
https://doi.org/10.1158/0008-5472.can-21-2693
Autor:
Biagio Ricciuti, Jieun Son, Jeffrey J. Okoro, Alessia Mira, Enrico Patrucco, Yoonji Eum, Xinan Wang, Raymond Paranal, Haiyun Wang, Mika Lin, Heidi M. Haikala, Jiaqi Li, Yue Xu, Joao Victor Alessi, Chhayheng Chhoeu, Amanda J. Redig, Jens Köhler, Kshiti H. Dholakia, Yunhan Chen, Elodie Richard, Marie-Julie Nokin, David Santamaria, Prafulla C. Gokhale, Mark M. Awad, Pasi A. Jänne, Chiara Ambrogio
Publikováno v:
Clinical Cancer Research
Purpose:Activating missense mutations of KRAS are the most frequent oncogenic driver events in lung adenocarcinoma (LUAD). However, KRAS isoforms are highly heterogeneous, and data on the potential isoform-dependent therapeutic vulnerabilities are st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26aaf3a21c7123d8632c8ec31fa75511
http://hdl.handle.net/2318/1855101
http://hdl.handle.net/2318/1855101
Autor:
Pınar Özden, Eser, Raymond M, Paranal, Jieun, Son, Elena, Ivanova, Yanan, Kuang, Heidi M, Haikala, Ciric, To, Jeffrey J, Okoro, Kshiti H, Dholakia, Jihyun, Choi, Yoonji, Eum, Atsuko, Ogino, Pavlos, Missios, Dalia, Ercan, Man, Xu, Michael J, Poitras, Stephen, Wang, Kenneth, Ngo, Michael, Dills, Masahiko, Yanagita, Timothy, Lopez, Mika, Lin, Jeanelle, Tsai, Nicolas, Floch, Emily S, Chambers, Jennifer, Heng, Rana, Anjum, Alison D, Santucci, Kesi, Michael, Alwin G, Schuller, Darren, Cross, Paul D, Smith, Geoffrey R, Oxnard, David A, Barbie, Lynette M, Sholl, Magda, Bahcall, Sangeetha, Palakurthi, Prafulla C, Gokhale, Cloud P, Paweletz, George Q, Daley, Pasi A, Jänne
Publikováno v:
Science translational medicine
The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in EGFR-mutant non–small cell lung cancer is limited by the development of drug resistance. One mechanism of EGFR inhibitor resistance occurs through amplification
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::22efb640067814269983395f20ecc3cd
https://pubmed.ncbi.nlm.nih.gov/34516823
https://pubmed.ncbi.nlm.nih.gov/34516823
Autor:
Emily S. Chambers, Alwin Schuller, Stephen Wang, Dalia Ercan, Mika Lin, Pınar Özden Eser, Raymond M. Paranal, Nicolas Floc'h, Sangeetha Palakurthi, Alison D. Santucci, Jeffrey J. Okoro, Geoffrey R. Oxnard, Man Xu, Kenneth H. Ngo, Jeanelle Tsai, Ciric To, Lynette M. Sholl, George Q. Daley, Michael Dills, Pavlos Missios, Kesi Michael, Paul D. Smith, Yoonji Eum, Magda Bahcall, Yanan Kuang, David A. Barbie, Masahiko Yanagita, Jennifer C. Heng, Rana Anjum, Prafulla C. Gokhale, Elena Ivanova, Jieun Son, Kshiti Dholakia, Heidi M. Haikala, Darren Cross, Jihyun Choi, Michael J. Poitras, Pasi A. Jänne, Timothy Lopez, Cloud P. Paweletz, Atsuko Ogino
Publikováno v:
Science Translational Medicine. 13
A subset of drug-resistant EGFR -mutant MET -amplified lung cancer switches oncogenic dependence to MET and is treatable with MET inhibitor monotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f7c7b3de9b86168add52ec03c24e84e
https://doi.org/10.1126/scitranslmed.abb3738
https://doi.org/10.1126/scitranslmed.abb3738